WallStreetZenWallStreetZen

NASDAQ: BLTE
Belite Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BLTE

Based on 6 analysts offering 12 month price targets for Belite Bio Inc

Min Forecast
$132.00-23.22%
Avg Forecast
$198.00+15.16%
Max Forecast
$266.00+54.71%

Should I buy or sell BLTE stock?

Based on 6 analysts offering ratings for Belite Bio Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BLTE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BLTE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BLTE stock forecasts and price targets.

BLTE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-13
lockedlocked$00.00+00.00%2026-03-03
lockedlocked$00.00+00.00%2026-03-03
lockedlocked$00.00+00.00%2026-01-26
lockedlocked$00.00+00.00%2025-12-02
Benchmark
Top 11%
90
Strong BuyMaintains$132.00-23.22%2025-10-31

1 of 1

Forecast return on equity

Is BLTE forecast to generate an efficient return?

Company
91.9%
Industry
68.34%
Market
160.77%
BLTE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BLTE forecast to generate an efficient return on assets?

Company
90.72%
Industry
31.48%
BLTE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BLTE earnings per share forecast

What is BLTE's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$2.11
Avg 2 year Forecast
-$2.38
Avg 3 year Forecast
$4.00

BLTE revenue forecast

What is BLTE's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$23.0M
Avg 2 year Forecast
$135.9M
Avg 3 year Forecast
$432.5M

BLTE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BLTE$171.93$198.00+15.16%Strong Buy
ACLX$114.89$115.83+0.82%Hold
PTGX$104.72$107.39+2.54%Strong Buy
KYMR$89.87$119.57+33.06%Strong Buy
APGE$88.47$111.73+26.29%Strong Buy
View Top Biotech Stocks

Belite Bio Stock Forecast FAQ

Is Belite Bio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: BLTE) stock is to Strong Buy BLTE stock.

Out of 6 analysts, 4 (66.67%) are recommending BLTE as a Strong Buy, 2 (33.33%) are recommending BLTE as a Buy, 0 (0%) are recommending BLTE as a Hold, 0 (0%) are recommending BLTE as a Sell, and 0 (0%) are recommending BLTE as a Strong Sell.

If you're new to stock investing, here's how to buy Belite Bio stock.

What is BLTE's earnings growth forecast for 2026-2028?

(NASDAQ: BLTE) Belite Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.06%.

Belite Bio's earnings in 2026 is -$77,611,000.On average, 10 Wall Street analysts forecast BLTE's earnings for 2026 to be -$82,889,296, with the lowest BLTE earnings forecast at -$162,694,339, and the highest BLTE earnings forecast at $78,070,151. On average, 8 Wall Street analysts forecast BLTE's earnings for 2027 to be -$93,629,105, with the lowest BLTE earnings forecast at -$183,898,577, and the highest BLTE earnings forecast at -$3,304,557.

In 2028, BLTE is forecast to generate $157,163,140 in earnings, with the lowest earnings forecast at $94,069,712 and the highest earnings forecast at $235,862,730.

What is BLTE's revenue growth forecast for 2026-2028?

(NASDAQ: BLTE) Belite Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.18%.

Belite Bio's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast BLTE's revenue for 2026 to be $902,852,082, with the lowest BLTE revenue forecast at $0, and the highest BLTE revenue forecast at $7,435,252,440. On average, 8 Wall Street analysts forecast BLTE's revenue for 2027 to be $5,345,907,164, with the lowest BLTE revenue forecast at $2,101,934,063, and the highest BLTE revenue forecast at $7,963,981,502.

In 2028, BLTE is forecast to generate $17,014,139,300 in revenue, with the lowest revenue forecast at $14,457,828,700 and the highest revenue forecast at $20,599,976,654.

What is BLTE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BLTE) forecast ROA is 90.72%, which is higher than the forecast US Biotechnology industry average of 31.48%.

What is BLTE's Price Target?

According to 6 Wall Street analysts that have issued a 1 year BLTE price target, the average BLTE price target is $198.00, with the highest BLTE stock price forecast at $266.00 and the lowest BLTE stock price forecast at $132.00.

On average, Wall Street analysts predict that Belite Bio's share price could reach $198.00 by Apr 13, 2027. The average Belite Bio stock price prediction forecasts a potential upside of 15.16% from the current BLTE share price of $171.93.

What is BLTE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BLTE) Belite Bio's current Earnings Per Share (EPS) is -$2.31. On average, analysts forecast that BLTE's EPS will be -$2.11 for 2026, with the lowest EPS forecast at -$4.14, and the highest EPS forecast at $1.98. On average, analysts forecast that BLTE's EPS will be -$2.38 for 2027, with the lowest EPS forecast at -$4.67, and the highest EPS forecast at -$0.08. In 2028, BLTE's EPS is forecast to hit $4.00 (min: $2.39, max: $6.00).

What is BLTE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BLTE) forecast ROE is 91.9%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.